Andecaliximab clinical trials
Andecaliximab is named as an intervention in 2 current clinical trials in our USA register. None are recruiting at the moment. The most common phase is Phase 1/2. The lead sponsor is Ashibio Inc. The most-studied condition is Heterotopic Ossification (HO).
Where Andecaliximab is approved
All regulators →- 1 EU orphan designation, most recently for treatment of fibrodysplasia ossificans progressiva (19 Feb 2024, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Andecaliximab works
All drug targets →- Matrix metalloproteinase 9 inhibitor InhibitorTarget: MMP9 matrix metallopeptidase 9✓ In ChEMBL and the Guide to Pharmacology
- Gastric adenocarcinomaPhase 3
- Gastroesophageal junction adenocarcinomaPhase 3
- Ulcerative colitisPhase 3
- Fibrodysplasia ossificans progressivaPhase 2/3
- Crohn diseasePhase 2
- Cystic fibrosisPhase 2
- Rheumatoid arthritisPhase 2
- Breast cancerPhase 1
- Chronic obstructive pulmonary diseasePhase 1
- Colorectal cancerPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3833374, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9510, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Andecaliximab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Andecaliximab
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT06508021 · Fibrodysplasia Ossificans Progressiva
|
Phase 2/3 | Active, closed | Ashibio Inc | USA |
|
A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.
NCT07024407 · Heterotopic Ossification (HO)
|
Phase 1/2 | Active, closed | Ashibio Inc | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Andecaliximab
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Ashibio Inc | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
Questions about Andecaliximab trials
How many clinical trials are testing Andecaliximab?
2 current trials in our USA register name Andecaliximab as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Andecaliximab trials recruiting patients?
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors Andecaliximab clinical trials?
The lead sponsor is Ashibio Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Andecaliximab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Andecaliximab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Andecaliximab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.